Bain Capital Life Sciences to invest $200m in Vivo Capital-backed Seran Bioscience.

Bain Capital Life Sciences, an investment company, agreed to invest $200m in Vivo Capital-backed Seran Bioscience, a contract development and manufacturing organization. "This transaction is a significant milestone in Serán’s evolution, which will enable us to rapidly scale our clinical manufacturing capability to support launches of new medicines, as well as serve new clients seeking state-of-the-art commercial capacity. We are proud to have the additional support and resources of a preeminent life sciences investor in Bain Capital who shares our vision for expanding Serán’s science-based drug development capabilities to enable commercial manufacturing of complex medicines,” Dan Smithey, Seran Bioscience Co-Founder and CEO.